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Colitis-associated cancer (CAC) is the most serious complication of inflammatory bowel disease. Proinflam-
matory cytokines have been suggested to regulate preneoplastic growth during CAC tumorigenesis. Inter-
leukin 6 (IL-6) is a multifunctional NF-kB-regulated cytokine that acts on epithelial and immune cells. Using
genetic tools, we now demonstrate that IL-6 is a critical tumor promoter during early CAC tumorigenesis.
In addition to enhancing proliferation of tumor-initiating cells, IL-6 produced by lamina propria myeloid cells
protects normal and premalignant intestinal epithelial cells (IECs) from apoptosis. The proliferative and
survival effects of IL-6 are largely mediated by the transcription factor Stat3, whose IEC-specific ablation
has profound impact on CAC tumorigenesis. Thus, the NF-kB-IL-6-Stat3 cascade is an important regulator
of the proliferation and survival of tumor-initiating IECs.INTRODUCTION
Colorectal cancer (CRC) is one of the most common fatal malig-
nancies worldwide (Weir et al., 2003). CRC develops in 5% of
the adult population in the United States, and almost half of
the affected individuals will die from this disease (Weir et al.,
2003). In patients with inflammatory bowel disease (IBD), such
as ulcerative colitis (UC), the risk of CRC development is much
higher than in the general population (Langholz et al., 1992).
Long-standing UC predisposes to development of colitis-asso-
ciated cancer (CAC), the major cause of death in UC patients
(Eaden et al., 2001). It has been proposed that noxious
compounds released during chronic colonic inflammationdamage DNA and/or alter cell proliferation or survival, thereby
promoting oncogenesis (Meira et al., 2008). While chronic
inflammation may contribute to oncogenic mutagenesis through
production of reactive oxygen and nitrogen species (Hussain
et al., 2003), experimental evidence suggests that it mainly
acts as a tumor promoter rather than as an initiator (Greten
and Karin, 2005).
The tumor-promoting effect of inflammation is now widely
recognized and better understood (Coussens and Werb, 2002;
Karin et al., 2006). Immune cells, which often infiltrate tumors
and preneoplastic lesions, produce a variety of cytokines and
chemokines that propagate a localized inflammatory response
and also enhance the growth and survival of premalignant cellsSIGNIFICANCE
Tumor development and growth are driven in many cases by inflammatory cells, which produce cytokines that stimulate the
growth and survival of malignant cells. Identification of such cytokines and their mechanism of action is of importance
because inhibition of protumorigenic cytokine action may offer therapeutic and preventive avenues. In previous work, we
have shown that NF-kB activation in myeloid cells stimulates the proliferation of premalignant intestinal epithelial cells
(IECs) in colitis-associated cancer (CAC). Here we identify IL-6 as a critical NF-kB-dependent protumorigenic cytokine
produced by lamina propria myeloid cells that stimulates the survival and proliferation of premalignant IECs. These effects
of IL-6 are mediated by the oncogenic transcription factor Stat3. Therefore, IL-6 and Stat3 may be useful targets for preven-
tion and treatment of CAC.Cancer Cell 15, 103–113, February 3, 2009 ª2009 Elsevier Inc. 103
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2007; Pikarsky et al., 2004). We have found that NF-kB-driven
cytokine production by myeloid cells is instrumental in CAC
tumor growth, whereas NF-kB activation in intestinal epithelial
cells (IECs) promotes the survival of newly emerging premalig-
nant cells (Greten et al., 2004).
These studies suggested that cytokines or growth factors
produced upon NF-kB activation in intestinal myeloid cells stim-
ulate the proliferation of premalignant IECs generated during
early stages of CAC tumorigenesis. Inactivation of NF-kB in
myeloid cells through ablation of IKKb, the protein kinase
required for its activation, inhibits production of inflammatory
mediators, including cytokines such as IL-6 and TNF-a, and
prevents IEC proliferation during CAC induction. As a result,
tumor load is reduced due to a decrease in tumor frequency
and size (Greten et al., 2004). One of the NF-kB-dependent
tumor growth factors released by myeloid cells could be IL-6,
a multifunctional cytokine important for immune responses,
cell survival, apoptosis, and proliferation (Kishimoto, 2005). IL-
6 binds to soluble or membrane-bound IL-6 receptor (IL-6Ra)
polypeptides that signal by interacting with the membrane-asso-
ciated gp130 subunit, whose engagement triggers activation of
Janus kinases (JAKs), and the downstream effectors Stat3,
Shp2-Ras, and phosphatidylinositol 3-kinase (PI3K)-Akt (Kishi-
moto, 2005). IL-6 is also critical for T cell survival and differenti-
ation and therefore has a central pathogenic role in T cell-depen-
dent autoimmune disorders, including IBD (Atreya et al., 2000;
Strober et al., 2007). By regulating the differentiation and survival
of pathogenic T helper (Th) cells, IL-6 can perpetuate chronic
inflammation and ensure the continuous production of cytokines
and growth factors required for malignant cell survival and
growth. IL-6 also has an important role in tissue homeostasis
and regeneration (Dann et al., 2008; Tebbutt et al., 2002), sug-
gesting that it may have direct prosurvival and protumorigenic
effects. Several studies have demonstrated a correlation
between circulating or local IL-6 levels and the clinical activity
of IBD (Atreya and Neurath, 2005). IL-6 protein and mRNA are
also often upregulated in serum and tumor samples of humans
and mice suffering from breast, prostate, lung, liver, and colon
cancer (Heikkila et al., 2008). IL-6 enhances the proliferation of
human colon carcinoma cells in vitro, and interference with IL-
6 signaling during late stages of CAC development slows down
tumor growth (Becker et al., 2004, 2005). However, it has not
been determined whether IL-6 is also involved in tumor promo-
tion and proliferation of premalignant IECs during early stages
of CAC. Furthermore, during late stages of CAC development
in a model with disrupted TGF-b signaling in T cells, IL-6 was
found to be produced mainly by T cells (Becker et al., 2004),
whereas genetic experiments that we conducted have revealed
that IL-6 is produced mainly by myeloid cells during early stages
of CAC (Greten et al., 2004). The exact signaling pathways
through which IL-6 promotes tumor development and growth
have not been established.
Here we show that IL-6, which is produced in an NF-kB-
dependent manner in innate immune cells within the lamina
propria in response to intestinal injury, regulates the survival
and proliferation of IECs and their preneoplastic derivatives
during acute colonic inflammation and CAC induction. The cyto-
protective and protumorigenic effects of IL-6 are mainly due to104 Cancer Cell 15, 103–113, February 3, 2009 ª2009 Elsevier Inc.Stat3 activation. Ablation of Stat3 in IECs effectively inhibits
CAC induction and growth, demonstrating the critical oncogenic
function of this cytokine-activated transcription factor.
RESULTS
Ablation of IL-6 Reduces CAC Tumorigenesis
IKKb-dependent NF-kB activation in myeloid cells controls
production of cytokines and growth factors that stimulate
neoplastic growth in mice subjected to CAC induction (Greten
et al., 2004). One of these factors may be the inflammatory cyto-
kine IL-6, whose expression during colitis induction is diminished
by inactivation of IKKb in myeloid cells. As inhibition of IL-6
signaling slows down the growth of adenomas during late-stage
CAC tumorigenesis (Becker et al., 2004), we sought to examine
the impact of complete IL-6 deficiency on CAC development
and determine whether it acts as a tumor promoter. We therefore
injected wild-type (WT) and Il6/ mice with the procarcinogen
azoxymethane (AOM) followed by three rounds of dextran
sodium sulfate (DSS) exposure to elicit colitis. As expected,
DSS exposure increased colonic IL-6 production (see Figure S1
available online). The IL-6 deficiency decreased tumor numbers
in mice treated with either high or low doses of DSS (Figures 1A
and 1B).
Notably, the absence of IL-6 had a stronger effect when mice
were treated with a lower dose of DSS. Tumor size was also
reduced (Figure 1C), and Il6/ mice exhibited a higher fre-
quency of smaller adenomas than WT mice (Figure 1D). Corre-
spondingly, average tumor load, a sum of the diameters of all
tumors in a given mouse (Neufert et al., 2007) was significantly
lower in ll6/ mice (Figure 1E). All of the tumors analyzed were
adenomas, and no carcinomas were noted. IL-6 status did not
exert a significant effect on the proportion of low- or high-grade
dysplastic adenomas (data not shown). Taken together, these
data indicate that IL-6 is important for both tumor development
and tumor growth in CAC.
IL-6 Regulates Survival and Proliferation of IECs
Differences in tumor multiplicity and load may be explained
by altered proliferation and/or death of tumor progenitors.
Decreased tumor multiplicity in Il6/ mice suggested that IL-6
may be involved in early tumor promotion, which in this model
is linked to inflammation. To determine the role of IL-6 in inflam-
mation, we treated WT and Il6/ mice with DSS to induce acute
colitis. Upon DSS treatment, Il6/ mice exhibited more severe
colitis with greater body weight loss than WT mice (data not
shown), shortening of the colon and loss of crypt structure, ulcer-
ation, and infiltration of inflammatory cells (Figures 2A–2C),
similar to previous reports (Dann et al., 2008; Tebbutt et al.,
2002).
DSS-exposed Il6/ mice exhibited elevated IEC apoptosis
(Figure 2D). To examine whether IL-6 might regulate proliferation
of IECs in the inflamed colon, we injected naive and DSS-treated
mice with 5-bromo-2-deoxyuridine (BrdU), which incorporates
into newly synthesized DNA, and sacrificed the animals 3 hr later.
Staining with BrdU or Ki-67-specific antibodies did not reveal
any significant differences in basal crypt proliferation rates
between naive WT and Il6/ mice (data not shown). However,
IEC proliferation within crypts of Il6/ mice was slightly but
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(Figure 2E). These results were confirmed by immunohistochem-
ical determination of Ki-67-expressing cells in the crypts
(Figure 2F) and immunoblot analysis for proliferating cell nuclear
antigen (PCNA), whose levels were generally higher in WT
colonic lysates (Figure 2G). Therefore, IL-6 enhances the prolifer-
ation of IECs and increases their resistance to apoptosis with
potential effects on tissue regeneration. Presumably, IL-6 exerts
the same effects on premalignant IECs in mice treated with
AOM + DSS.
IL-6 Is Produced by Multiple Cell Types during CAC
Tumorigenesis
To gain further insights into the cellular source of IL-6 during
tumorigenesis, we generated reciprocal bone marrow chimeras
by introducing WT bone marrow into lethally irradiated Il6/
(WT/Il6/) or WT (WT/WT) hosts and Il6/ bone marrow
into Il6/ (Il6//Il6/) or WT (Il6//WT) mice. The extent
of repopulation was determined by flow cytometric analysis of
the congenic markers Ly5.1 and Ly5.2 and was routinely 93%–
98% for CD3+ T cells and 90%–95% for CD11b+ myeloid cells
Figure 1. IL-6 Controls Tumor Formation and Growth in a Mouse
Colitis-Associated Cancer Model
(A and B) Wild-type (WT) and Il6/ mice were subjected to an azoxymethane
(AOM)-based colitis-associated cancer (CAC) induction protocol using three
cycles of 2.5% (A) or 1.5% (B) dextran sodium sulfate (DSS) in drinking water.
Tumors were counted at the end of the 12 week CAC induction regimen. Data
represent average tumor numbers ± SD (n > 10). *p = 0.003 for (A); *p = 0.0001
for (B).
(C) Tumor sizes were determined using Spot software for microscopic tumors
or a caliper for macroscopic tumors. Average tumor size ± SD is shown;
*p = 0.012.
(D) Histogram showing size distribution of tumors.
(E) Average tumor load was determined by summing all tumor diameters for
a given animal. Results are averages ± SD (n > 7). *p = 0.047.(data not shown). The chimeric mice were subjected to the stan-
dard CAC induction protocol, and tumor multiplicity and load
were evaluated. Tumor numbers were markedly reduced when
IL-6 was inactivated in hematopoietic cells (Figure 3A). IL-6 defi-
ciency in bone marrow-derived cells also decreased tumor size
and load (Figures 3B and 3C). We observed an increase in tumor-
igenicity in Il6//WT mice in comparison with Il6//Il6/
mice, but the effect was not statistically significant (Figure 3A).
We have previously found a critical contribution of myeloid
cells to IL-6 production during the initial stage of DSS-induced
colitis (Greten et al., 2004). However, others who have con-
ducted their analyses during late stages of CAC tumor growth
have suggested that T cells are the major IL-6 producers, at least
in the model where TGF-b signaling is inactivated in T cells
(Becker et al., 2004). Another report has suggested that intestinal
dendritic cells are responsible for IL-6 production triggered by
proinflammatory stimuli (Denning et al., 2007). To determine
the cellular source of IL-6 during the colitis phase and in already
developed CAC, we performed immunohistochemical staining
with anti-IL-6 antibody. We found strong IL-6 expression in infil-
trating immune cells and weak but detectable expression in
epithelial cells both in the mucosa of DSS-challenged mice
and in CAC adenomas (Figure 3D). To further delineate cellular
sources of IL-6, we isolated lamina propria cells from colons of
CAC-bearing mice and from CAC adenomas using a protocol
that increases the yield of myeloid cells, which otherwise are
largely lost during the isolation procedure (Denning et al.,
2007). Intracellular cytokine staining and flow cytometry revealed
that lamina propria and tumor-infiltrating CD11c+ (dendritic cells)
and CD11b+ (macrophages) cells were the major IL-6 producers
during CAC growth, followed by CD3+ (T cells) cells (Figures 3E
and 3F). Analysis of IL-6 mRNA in cells sorted by fluorescence-
activated cell sorting (FACS) from lamina propria and CAC
adenomas confirmed that dendritic cells (DCs) followed by
macrophages are the major IL-6 producers (Figure 3G). Myeloid
cells were less abundant in the adenoma leukocyte population
than T cells (Figure 3H), but their overall contribution to IL-6
production was greater (Figure 3F and 3G).
IL-6 Is Important for Tumor Growth and Proliferation
We analyzed cell proliferation in WT and IL-6-deficient tumors.
PCNA nuclear staining was modestly decreased in Il6/
adenomas (Figure 4A), as was expression of PCNA mRNA
(Figure 4B). Analysis of Ki-67 expression revealed a small but sig-
nificant difference in proliferation rates between WT and IL-6-
deficient tumors (Figures 4C and 4D). Expression of cyclin D
was also lower in Il6/ tumors (Figure 4C), indicating decreased
growth capacity for the tumors in the absence of IL-6. Cyclin D2
mRNA expression was also decreased in total RNA prepared
from Il6/ colon tumors of CAC-bearing mice (Figure S4).
Immunoblot analysis of total colon lysates of WT and Il6/
CAC-bearing mice revealed marked downregulation of Stat3
phosphorylation, as well as significant decreases in proliferation
(PCNA) and inflammation (COX2 and MMP9) markers in Il6/
mice (data not shown). Therefore, IL-6 is important for tumor
growth and expression of prosurvival and proproliferative genes
during CAC tumorigenesis. However, since WT mice have higher
tumor loads, it is difficult to conclude whether the changes in
protein expression are a direct reflection of IL-6 deficiency orCancer Cell 15, 103–113, February 3, 2009 ª2009 Elsevier Inc. 105
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culty, we examined the consequences of IL-6 deficiency during
colitis induction and confirmed a considerable reduction in phos-
phorylated Stat3 in IECs from Il6 / mice (Figure 4E). We also
analyzed nuclear accumulation of phosphorylated Stat3 in acute
DSS-induced colitis and in CAC adenomas and found that abla-
tion of IL-6 resulted in weaker phospho-Stat3 nuclear staining,
while the frequency of phospho-Stat3-positive cells was not
different between WT and Il6/ mice (Figure S3). Therefore,
IL-6 (together with other cytokines) is an important Stat3 acti-
vator in IECs during acute DSS-induced colitis and tumor
growth. We also noted downregulation in IECs from Il6/ mice
of the antiapoptotic and cytoprotective proteins Hsp70 (Hsp72)
(data not shown) and Bcl-XL (Figure 5H), which were suggested
to mediate IEC survival (Rakoff-Nahoum et al., 2004) and whose
genes contain STAT-binding sites (Madamanchi et al., 2001). We
also analyzed expression of the tissue-protective factors Tff3,
which has been implicated in IL-6-mediated intestinal protection
during colitis (Tebbutt et al., 2002), and RegIIIg and found a small
reduction in the absence of IL-6 (Figure 4F).
A Critical Role for Epithelial Stat3 in IL-6-Dependent
Tumorigenesis
To decipher the molecular mechanisms that mediate effects of
IL-6 on IEC physiology and CAC development, we analyzed total
colon lysates of DSS-treated WT and Il6/ animals for activation
of various IL-6 effectors. Whereas the extent of activation of S6
Figure 2. IL-6 Is Required for Maintenance of Mucosal
Integrity
(A) WT and Il6/ mice exhibit colon shortening after 7 days of
2.5% DSS exposure.
(B) Mucosal histology was examined in WT and Il6/ mice
4 or 10 days after initiation of 2.5% DSS treatment by hema-
toxylin and eosin (H&E) staining of paraffin-embedded
sections. Scale bars = 50 mm.
(C) Colitis severity score after 3% DSS exposure was deter-
mined on day 10. Results are averages ± SD (n = 5). *p% 0.05.
(D) Apoptosis in colons of 3% DSS-treated mice was evalu-
ated by TUNEL staining on day 4 after DSS administration.
Scale bars = 50 mm.
(E) The extent of intestinal epithelial cell (IEC) proliferation in
colons of DSS-treated mice was determined by BrdU labeling
and immunohistochemistry. Scale bars = 50 mm.
(F) The percentage of Ki-67-positive cells among all crypt cells
in colons of DSS-treated mice was enumerated. Results are
averages ± SD (n = 6). *p = 0.001.
(G) Lysates of distal colons prepared on the indicated days
after initiation of 3% DSS treatment were analyzed for PCNA
expression by immunoblotting.
kinase (S6K), a target for PI3K/mTOR signaling,
and ERK, a target for Shp2-Ras signaling, was not
significantly altered by the absence of IL-6, Stat3
activation was considerably reduced (Figure 5A).
IL-6 signaling has also been reported to downmo-
dulate TGF-b/BMP signaling by inducing expres-
sion of its inhibitor Smad7 (Jenkins et al., 2005).
However, we did not observe increased amounts
of phospho-Smad2/3 in nuclei of IECs of Il6/
mice (Figure S5).
To determine the contribution of Stat3 in IECs to CAC tumor-
igenesis, we generated mice with a conditional Stat3 deletion in
enterocytes (Stat3DIEC mice) by crossing Stat3F/F mice (Takeda
et al., 1999) with villin-Cre mice (Madison et al., 2002). Stat3DIEC
mice, which were phenotypically normal, were almost
completely devoid of Stat3 protein in IECs (Figures 5B and 5C)
but retained Stat3 expression in lamina propria cells (Figure 5C).
A considerable reduction in total and phosphorylated Stat3 was
also seen in crude colonic lysates of Stat3DIEC mice (Figure 5D).
Stat3DIEC mice developed more severe DSS-induced colitis
than WT counterparts, with pronounced colonic ulceration and
body weight loss (Figures 5E and 5F). Expression of Hsp70
(Hsp72) and Bcl-XL was significantly downregulated in colonic
lysates and IECs of Stat3DIEC mice (Figures 5G and 5H). This
phenotype of Stat3DIEC mice was similar to that of Il6/ mice,
although Stat3DIEC mice developed more severe colitis and dis-
played more pronounced epithelial injury. Stat3DIEC mice also
exhibited decreased IEC proliferation after DSS exposure (Fig-
ure 6A). Most importantly, hardly any adenomas were found in
AOM + DSS-treated Stat3DIEC mice (Figure 6B), an effect also
somewhat greater than the one caused by ablation of IL-6. In
addition, Stat3-deficient adenomas were smaller than WT coun-
terparts (Figures 6C and 6D). Immunohistochemical staining
confirmed absence of Stat3 in Stat3DIEC cancer cells, indicating
that the tumors did not originate from progenitor cells that
escaped Cre-mediated deletion (data not shown). DSS-induced
apoptosis of IECs was increased in Stat3DIEC mice in106 Cancer Cell 15, 103–113, February 3, 2009 ª2009 Elsevier Inc.
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(Figure 6E). Therefore, epithelial Stat3 is required for transduc-
tion of tumor-promoting signals from IL-6 and other cytokines
and is important to maintain survival and regenerative capacity
of IECs.
IL-6 Is Continuously Required for Stimulation
of CAC Tumor Growth
WT mice were treated with recombinant IL-6 and the so-called
hyper-IL-6 recombinant protein, which triggers IL-6 trans-
signaling (Fischer et al., 1997; Mitsuyama et al., 2006). Hyper-
IL-6 treatment during colitis or at late stages of CAC growth
increases T cell survival and tumor burden without affecting
tumor multiplicity (Becker et al., 2004). We confirmed that
continuous treatment with either recombinant IL-6 or hyper-IL-6
during early or late stages of CAC resulted in a significant
increase in tumor size (Figures 7A–7E). As reported previously,
effects on tumor multiplicity during late CAC development
were marginal (Figure 7C). However, when IL-6 or hyper-IL-6
was administered during early CAC induction, they did enhance
tumor multiplicity (Figures 7D–7F). Treatment with recombinant
Figure 3. IL-6 Produced by Bone Marrow-Derived
Cells Is Required for CAC Tumorigenesis
(A) Tumor multiplicity in radiation chimeras subjected to induc-
tion of CAC using 2.5% DSS. Results are averages ± SD
(n > 8). *p < 0.01.
(B) Paraffin-embedded sections of adenoma-containing
colons stained with H&E. Scale bars = 100 mm.
(C) Average tumor loads in radiation chimeras. Results are
averages ± SD (n = 5). NS, not significant; *p < 0.01.
(D) Immunohistochemical analysis of IL-6 expression in DSS-
treated colons (normal mucosa) or CAC-bearing colons of WT
mice. Scale bars = 50 mm.
(E and F) Intracellular IL-6 cytokine staining of PMA + ionomy-
cin-restimulated tumor-infiltrating cells analyzed by flow
cytometry. Results are averages ± SD (n = 3).
(E) Percentages of IL-6-expressing cells in each given popula-
tion (dendritic cells [DCs], macrophages [Mf], T cells, and
B cells).
(F) Percentages of each population positive for IL-6 cells
among all tumor-infiltrating cells.
(G) Macrophages (CD45+CD11b+CD11c), dendritic cells
(CD45+CD11b+CD11c+), and T cells (CD45+CD8a+ or
CD45+CD4+) isolated by fluorescence-activated cell sorting
were analyzed for IL-6 mRNA by qRT-PCR. Tumor population =
tumor-infiltrating cells from pooled tumors; LP population =
lamina propria cells from colons from which the tumors were
excised.
(H) Percentage of macrophages (CD11b+), T cells (CD3+), and
dendritic cells (CD11c+) in total lamina propria cells isolated
from pooled CAC tumors from WT mice.
IL-6 or hyper-IL-6 also enhanced Stat3 phosphory-
lation in colon (Figure 7G) and, importantly, resulted
in elevated serum levels of IL-6 (Figure S6), in
agreement with previously published data (Peters
et al., 1998). Thus, IL-6 signaling can affect both
tumor multiplicity and size if activated during early
stages of CAC induction and therefore has an impact on tumor
formation and growth.
IL-6 and TNF-a Cross-Regulation
and the Role of TNF-a in CAC
TNF-a is another NF-kB-regulated cytokine that is critical for IBD
development in humans and mice (Kollias et al., 1999). CAC
development and growth have been found to be attenuated in
TNF receptor 1 (TNFR1) knockout mice or in mice treated with
a soluble TNFR2 decoy (Enbrel) (Popivanova et al., 2008).
However, the methods used in this previous study did not distin-
guish between the involvement of TNF-a and lymphotoxin-a,
which also signals through TNFR1 and is neutralized by Enbrel.
We therefore examined whether monoclonal antibodies to
mouse TNF-a can decrease CAC development. Indeed, treat-
ment with anti-TNF-a antibodies at late stages of CAC reduced
the number of macroscopically detectable tumors and
decreased average tumor load in CAC-bearing mice (Figures
S7A and S7B). TNF-a blockade also inhibited expression of IL-6
mRNA in colonic lysates from CAC-bearing mice (Figure S7C),
which may partially explain how TNF-a controls tumor growth.Cancer Cell 15, 103–113, February 3, 2009 ª2009 Elsevier Inc. 107
Cancer Cell
IL-6-Stat3 Signaling in Colitis-Associated CancerHowever, we also found that IL-6 can affect TNF-a expression.
Blockade of IL-6 trans-signaling slightly decreased TNF-a mRNA
expression in colon, while administration of hyper-IL-6 resulted
in a modest increase in TNF-a mRNA (Figure S7D). Thus, the
two NF-kB-dependent cytokines IL-6 and TNF-a cross-regulate
each other during CAC development to enhance chronic inflam-
mation and tumorigenesis.
DISCUSSION
Although cell-autonomous events such as proliferation and
death evasion control tumor development, the tumor microenvi-
ronment also makes a major contribution and influences the
physiology of malignant cells (Radisky and Bissell, 2004). Nearly
all tumors contain inflammatory and immune cells, such as
dendritic cells, macrophages, and lymphocytes, which produce
cytokines and other factors that promote tumor growth and
survival (Balkwill et al., 2005; Coussens and Werb, 2002; Lin
and Karin, 2007). The most obvious tumor-promoting role of
immune cells is manifested in inflammation-associated cancers,
where tumors arise and grow at sites of chronic inflammation. In
previous work, we found that inhibition of NF-kB activation in
myeloid cells, exerted through the cell-type-specific ablation of
IKKb, inhibits the proliferation of premalignant IECs in a mouse
model of CAC (Greten et al., 2004). Based on these results, we
concluded that myeloid cells in the lamina propria of mice sub-
jected to CAC induction produce cytokines that stimulate the
proliferation of adjacent premalignant IECs, which harbor acti-
vating b-catenin mutations (Greten et al., 2004). The results
described above suggest that one of these cytokines is IL-6.
Figure 4. IL-6 Regulates Cell Proliferation and Expres-
sion of Genes Involved in Proliferation, Survival, and
Inflammation
(A) Colons of adenoma-bearing mice were stained with anti-
PCNA antibody. Scale bars = 50 mm.
(B) Lysates of distal colons of adenoma-bearing mice were
prepared, and PCNA mRNA expression was analyzed by
qRT-PCR. Results are averages ± SD (n = 3). *p < 0.05.
(C) Sections of adenoma-bearing colons were stained with
antibodies to cyclin D. Scale bars = 50 mm.
(D) Percentages of Ki-67-positive cells within colonic crypts.
Results are averages ± SD (n = 6). *p = 0.005.
(E) IECs from mice treated with 2.5% DSS were purified on day
10. Expression of the indicated proteins was analyzed by
immunoblotting after gel separation.
(F) RegIIIg and Tff3 mRNA expression was analyzed by qRT-
PCR. Results are averages ± SD (n = 3). *p < 0.05 (left);
*p = 0.05 (right).
Using genetic and pharmacological tools, we
demonstrated that IL-6 is an important regulator
of CAC development and growth. However, IL-6
did not have significant effect on early tumor
promotion in the CAC model since its absence
did not alter the distribution of high- and low-grade
dysplastic adenomas. As reported by other
groups, it is plausible that in other cancer models,
IL-6 may be an important player in tumor progres-
sion and invasiveness (Poutahidis et al., 2007).
The major protumorigenic IL-6 effector is the transcription
factor Stat3, whose ablation in IECs also results in decreased
tumor multiplicity and growth. Although Stat3 has been known
as an oncogenic transcription factor (Bromberg et al., 1999;
Sriuranpong et al., 2003; Wang et al., 2004; Yu et al., 2007), it
has only recently been proven to be critical for tumor initiation
and growth in vivo in a model of skin cancer (Chan et al., 2004;
Kataoka et al., 2008). Here, we demonstrate that specific Stat3
ablation in intestinal epithelial cells interferes with tumor forma-
tion and tumor growth in a mouse model of CAC.
IL-6-deficient mice developed fewer and smaller adenomas
than WT mice. Also, fewer myeloid cells (macrophages and
neutrophils) were recruited to IL-6-deficient colons after DSS
administration (Figure S2), consistent with a role for IL-6 and
IL-6-like signaling in leukocyte migration (Romano et al., 1997;
Sander et al., 2008). However, it should be noted that in acute
DSS-induced colitis, leukocyte recruitment not only depends
on direct IL-6-dependent signals but also is regulated by the
degree of injury. We also found fewer IL-17A-producing T helper
(Th17) cells in colons of Il6/mice subjected to CAC (Figure S2),
which is in line with the role of IL-6 in Th17 lineage differentiation
(Bettelli et al., 2006; Veldhoen et al., 2006). We do not rule out
indirect effects of IL-6 on CAC development due to its impact
on immune cells; however, IEC-specific ablation of the IL-6
target Stat3 phenocopies IL-6 ablation as far as CAC induction
and growth are concerned. However, IKKb ablation in myeloid
cells, which affects IL-6 induction, does not compromise IEC
survival (Greten et al., 2004). Thus, in addition to control of IL-6
expression, NF-kB may also be involved in production of
damage-inducing cytokines, whose effect becomes more108 Cancer Cell 15, 103–113, February 3, 2009 ª2009 Elsevier Inc.
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Acute Colitis
(A) Mice were exposed to 2.5% DSS. Colonic lysates were
prepared at the indicated time points and analyzed for expres-
sion and phosphorylation of the indicated proteins.
(B) Deletion of Stat3 in IECs of Stat3DIEC mice was examined
by immunoblotting of IEC lysates.
(C) Deletion of Stat3 in colons of Stat3DIEC mice was analyzed
by immunohistochemistry with anti-Stat3 antibody. Scale bar =
50 mm.
(D) Total colon lysates of WT and Stat3DIEC mice were analyzed
for Stat3 expression and phosphorylation by immunoblot
analysis.
(E) Increased susceptibility of Stat3DIEC mice to DSS-induced
colitis. Colons of WT and Stat3DIEC mice were analyzed by
sectioning and H&E staining 10 days after initiation of 2.5%
DSS exposure. Scale bars = 100 mm.
(F) Body weights of the indicated mice were measured 10 days
after initiation of 2.5% DSS exposure. Results show
percentage of body weight on day 0 and are averages ± SD
(n = 6). *p < 0.05.
(G and H) Total colon lysates (G) or IEC lysates (H) from mice on
day 10 after 2.5% DSS administration were analyzed for
expression of the indicated proteins by immunoblotting.pronounced in the absence of IL-6. Candidates for such cyto-
kines are TNF-a and Fas ligand (FasL), which do not induce
apoptosis in normal IECs and whose proapoptotic effect can
be partially blocked by IL-6 or by activation of Stat3 (Dann
et al., 2008; Yamaoka et al., 2008).
Our current results affirm our earlier conclusions that during
early CAC induction, when it acts as a tumor promoter, IL-6
is produced mainly by myeloid cells. Nonetheless, we also
detected IL-6 production by other immune cell types, such as
T cells, and by IECs. Correspondingly, mice lacking IL-6 in
bone marrow-derived cells exhibited fewer tumors, with
a substantial reduction in overall CAC tumor load. While the
role of immune cell IL-6 seems greater in cancers associated
with underlying chronic inflammation, IL-6 produced by epithelial
and cancer cells may still contribute to tumorigenesis in models
without an obvious inflammatory component (Ancrile et al., 2007;
Gao et al., 2007; Grivennikov and Karin, 2008; Hodge et al., 2005;
Sansone et al., 2007).
By binding to its gp130-associated receptor, IL-6 activates
three separate signaling pathways, namely Shp2-Ras-ERK,
JAK1/2-Stat3, and PI3K-Akt-mTOR (Kishimoto, 2005). Our
results suggest that among these, Stat3 is a critical IL-6 effec-
tor in CAC induction. Stat3 is highly phosphorylated not only
during DSS-induced colitis in mice but also in the mucosa
and lamina propria of human IBD patients (Fu, 2006). Stat3
has been found to be activated in various adenomas and carci-
nomas, although the mechanisms of its activation are obscure
(Klampfer, 2008; Kusaba et al., 2005). Stat3 induces expression
of genes important for proliferation (such as cyclin D and PCNA)
and suppression of apoptosis (Bcl-XL, Bcl-2, and Mcl-1)C(Becker et al., 2005; Klampfer, 2008). Stat3 signaling in IECs
also controls expression of the inducible form of the cytopro-
tective chaperone Hsp70 (Hsp72), known to be encoded by a
Stat3 target gene (Madamanchi et al., 2001), and Bcl-XL
but has an insignificant effect on the small heat-shock protein
Hsp27, also thought to protect the intestinal mucosa from
damage (Rakoff-Nahoum et al., 2004). Hsp27 was previously
shown to be controlled by p38 MAPK signaling (Sakurai et al.,
2008). Other cytoprotective factors regulated by IL-6 in IECs
are the intestinal trefoil factor (ITF)/Tff3 and RegIIIg, which
are important for intestinal protection during DSS-induced
colitis (Tebbutt et al., 2002). However, Tff3 expression is
presumably regulated by the Stat3 pathway (Tebbutt et al.,
2002). The remaining Stat3 activation seen in IECs of Il6/
mice and the more severe manifestations of DSS-induced
colitis and decreased tumorigenesis seen in Stat3DIEC mice
imply that IL-6 is not the only Stat3 activator. This suggests
the possible involvement of other cytokines that play cytopro-
tective and proliferative roles, in particular EGF, IL-22 (Sugimoto
et al., 2008; Zheng et al., 2008), IL-11 (Ernst et al., 2008; see
also Bollrath et al. [2009] in this issue of Cancer Cell), and
others.
Stat3 inhibitors reduce growth and promote apoptosis in colon
cancer cell lines (Rivat et al., 2004). Conversely, mice lacking
SOCS3, a negative regulator of receptor-mediated activation
of Stat3 (Suzuki et al., 2001), in IECs show enhanced CAC devel-
opment (Rigby et al., 2007). Similarly, gp130 mutations that
prevent SOCS3 binding lead to Stat3 hyperactivation and spon-
taneous gastrointestinal tumorigenesis (Ernst et al., 2008;
Jenkins et al., 2005; Judd et al., 2004; Bollrath et al., 2009).ancer Cell 15, 103–113, February 3, 2009 ª2009 Elsevier Inc. 109
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signaling also affects tumor growth during late stages of CAC
(Becker et al., 2004). Enhanced IL-6 trans-signaling or both clas-
sical and trans-signaling during late CAC development accel-
erate tumor growth without affecting tumor multiplicity (Figures
7A–7C). Interestingly, IL-6 signaling during that stage increases
TNF-a production, and interference with TNF-a signaling curtails
tumor growth and reduces IL-6 production. Thus, the beneficial
effect of TNF-a inhibition may be partially due to reduced IL-6
expression. While TNF-a can directly induce IL-6 production by
NF-kB-, NF-IL-6-, and AP-1-dependent mechanisms (Legrand-
Poels et al., 2000), it also can facilitate the recruitment and
survival of proinflammatory immune cells capable of IL-6 produc-
tion (Kollias et al., 1999). Conversely, IL-6 can directly induce
TNF-a transcription and sustains chronic inflammation, in partic-
ular by ensuring the continuous presence of TNF-a-producing
cells (Atreya et al., 2000). Such cross-regulation is not unique
to IL-6 and TNF-a since, for example, IL-1 can also induce IL-6
production (Legrand-Poels et al., 2000) and have an indirect
impact on immune cell recruitment (Dinarello, 1994). Indeed,
IL-1a released by necrotic hepatocytes induces IL-6 synthesis
(Sakurai et al., 2008), whereas IL-1b is involved in CAC develop-
ment (Garlanda et al., 2007; Xiao et al., 2007) and is also a well-
established IL-6 inducer in immune cells and even in IECs (Parikh
et al., 1997).
In summary, our results establish a role of IL-6 and Stat3
signaling in IECs during inflammation-associated colon carcino-
Figure 6. Stat3 Is Critical for CAC Tumorigenesis
(A) Percentage of Ki-67-positive cells in WT and Stat3DIEC colonic crypts 10
days after initiation of DSS exposure. Results are averages ± SD (n = 3).
*p = 0.03.
(B) Tumor multiplicity in WT and Stat3DIEC mice subjected to induction of CAC.
Results are averages ± SD (n = 8). *p = 0.004.
(C) Tumor size in WT and Stat3DIEC mice. Results are averages ± SD (n = 8).
*p = 0.012.
(D) Paraffin-embedded sections of adenoma-containing colons of WT and
Stat3DIEC mice were stained with H&E. Scale bars = 100 mm.
(E) Apoptosis in colons of DSS-treated mice was evaluated on day 4 after
DSS administration by TUNEL staining. Number of TUNEL-positive cells
per microscope field was determined. Results are averages ± SD (n = 3).
*p = 0.05.110 Cancer Cell 15, 103–113, February 3, 2009 ª2009 Elsevier Inc.genesis and create a rationale for the use of IL-6 blockers and
Stat3 inhibitors in the treatment and prevention of CAC.
EXPERIMENTAL PROCEDURES
Animals and Tumor Induction
Il6/ (Il6tm1Kopf/Il6tm1Kopf), villin-Cre (B6.SJL-Tg(vil-Cre)997Gum/J), and Ly5.1
and Ly5.2 congenic C57BL/6 mice were obtained from The Jackson Labora-
tory. Stat3F/F mice (Takeda et al., 1999) were obtained from C. Drake with
permission from S. Akira. Cre-negative mice were used as WT controls. All
mice were maintained in filter-topped cages on autoclaved food and water
at UCSD according to NIH guidelines, and all experiments were performed
in accordance with UCSD and NIH guidelines and regulations.
CAC was induced as described previously (Greten et al., 2004). Briefly, on
day 1, mice were injected intraperitoneally (i.p.) with 12.5 mg/kg azoxyme-
thane (AOM; National Cancer Institute) and maintained on regular diet and
water for 5 days. After 5 days, mice received water with 2.5% (unless stated
otherwise) dextran sulfate sodium (DSS; MP Biomedicals, molecular weight
35,000–50,000 kDa) for 5 days. After this, mice were maintained on regular
water for 14 days and subjected to two more DSS treatment cycles. On day
100, mice were injected i.p with 100 mg/kg 5-bromo-2-deoxyuridine (BrdU;
Sigma) and sacrificed 3 hr later. Macroscopic tumors were counted and
measured with a caliper. One half of the distal colon was taken as a tissue
sample and snap frozen in liquid nitrogen or maintained in RNA stabilization
solution (RNAlater, Ambion). The other half was fixed in 10% neutral buffered
formalin for 24 hr and transferred to 70% ethanol for subsequent paraffin
embedding and histological analysis. The clinical course of disease was fol-
lowed daily by measurement of body weight and monitoring for signs of rectal
bleeding or diarrhea.
IL-6 and TNF-a Agonists and Antagonists
Purified hyper-IL-6, recombinant IL-6, and sgp130Fc fusion protein have been
described previously (Fischer et al., 1997). Monoclonal antibody to mouse
TNF-a (C258D) and isotype control were generously provided by Centocor
Inc. These reagents were diluted in sterile PBS and injected i.p.
Antibodies
Fluorescent-labeled antibodies for flow cytometry were from eBioscience.
Immunoblot analysis and immunohistochemistry were carried out with the
following antibodies: anti-Cyclin D (1/2) (Upstate), anti-Ki-67 (Novocastra
Laboratories), anti-PCNA, anti-BrdU (BD Pharmingen), anti-Bcl-XL (BD Phar-
mingen and Cell Signaling), anti-COX2 (Cayman), anti-actin (Sigma), anti-
p-SHP2, anti-p-Stat3, anti-Stat3, anti-p-ERK, anti-ERK, and anti-p-S6 (Cell
Signaling). Anti-Hsp70 was from Santa Cruz Biotechnology or Stressgen,
and anti-tubulin antibodies were from Santa Cruz Biotechnology.
Histological Analysis
Colons were examined using 6 mm thick, 200 mm step serial sections stained
with hematoxylin and eosin. Using Scion Image for Windows, the greatest
width of each tumor was measured and recorded. The extent of inflammation
was measured and scored as described previously (Greten et al., 2004). For
TUNEL assay, an ApoAlert DNA Fragmentation Assay Kit (BD Clontech) or In
Situ Cell Death Kit (Roche) was used according to the manufacturer’s recom-
mendations. To determine BrdU incorporation, paraffin sections were stained
using a BrdU In-Situ Detection Kit (BD Pharmingen) according to the manufac-
turer’s recommendations. Scion Image for Windows was used to add
scale bars.
Immunohistochemistry and Immunoblotting
Paraffin-embedded slides were deparaffinized. Antigen unmasking was
carried out by incubation in 80C water bath in 10 mM sodium citrate buffer
with 0.1% Tween 20 overnight. Slides were incubated with primary antibodies
in PBS containing 1% BSA and 10% goat serum. Biotinylated secondary anti-
rat or anti-rabbit antibodies (BD Pharmingen) were added and incubated at
room temperature for 1 hr. Streptavidin-HRP (BD Pharmingen) was added,
and after 40 min the sections were stained with DAB substrate and counter-
stained with hematoxylin.
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IL-6-Stat3 Signaling in Colitis-Associated CancerTissue samples were homogenized in standard RIPA buffer, unless stated
otherwise, with a cocktail of protease and phosphatase inhibitors. Cyto-
plasmic and nuclear proteins were prepared using a NE-PER kit (Pierce)
according to the manufacturer’s instructions. Lysates were separated on
a 10%–15% SDS-polyacrylamide gels, and proteins were transferred to
PVDF membranes (Whatman). Membranes were blocked in PBST buffer
containing 5% skim milk for 1 hr at room temperature, probed with primary
antibodies and secondary HRP-conjugated antibodies (GE Healthcare UK),
and developed using ECL western blot detection reagent (Pierce).
Flow Cytometry and Cell Sorting
Isolated cells were stained with labeled antibodies in PBS with 2% fetal calf
serum and analyzed on a BD FACSCalibur or on an Accuri C6 flow cytometer.
For cell sorting, a BD FACSVantage cell sorter was used. Data were analyzed
using FlowJo or Accuri CFlow software.
Real-Time PCR Analysis
Total RNA was extracted using TRIzol (Invitrogen) or an RNeasy Plus kit
(QIAGEN). After DNase I treatment (Ambion), RNA was reverse transcribed
using an iScript kit (Bio-Rad). Real-time PCR was performed using SYBR
green (Bio-Rad) on a Bio-Rad iQ5 machine. Expression data were normalized
to cyclophilin or GAPDH mRNA expression. Data are presented in arbitrary
units and were calculated as 2(DCt cyclophilin  gene of interest). Primer sequences
are listed in Supplemental Experimental Procedures.
Statistical Analysis
Data are presented as averages ± SD and were analyzed by built-in t test using
Microsoft Excel software. p% 0.05 was considered significant.
Figure 7. IL-6 Signaling Stimulates Tumor Formation and
Growth
(A) Scheme of treatment with IL-6 agonists during late stage of CAC
growth. Mice were injected intraperitoneally (i.p.) with 2 mg hyper-IL-6,
5 mg recombinant IL-6 (rec IL-6), or control PBS every 3 days after the
last DSS cycle. Tumors were analyzed on day 100 after AOM injection.
(B) Number of tumors > 2 mm. Results are averages ± SD (n = 7).
*p < 0.05.
(C) Tumor multiplicity. Results are averages ± SD. NS, not significant.
(D) Scheme of treatment with IL-6 agonists during CAC induction.
Mice were injected i.p. with the same amount of IL-6 agonist as in
(A) on day 1, 5, and 8 of each DSS cycle. Tumors were analyzed
100 days after AOM injection.
(E) Average tumor load. Results are averages ± SD (n = 6). *p < 0.05.
(F) Tumor multiplicity. Results are averages ± SD (n = 6). *p < 0.05.
(G) Immunoblot analysis of colonic lysates from mice treated with
hyper-IL-6, recombinant IL-6, or PBS (control) after exposure to
2.5% DSS for 7 days. Mice were sacrificed on day 10, 30 min after
the last treatment.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Proce-
dures and seven figures and can be found with this article online at
http://www.cancercell.org/supplemental/S1535-6108(09)00002-6.
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